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Abstract
Introduction Double-peaked time distributions of the mortality
hazard function have been reported for breast cancer patients
from Western populations treated with mastectomy alone.
These are thought to reflect accelerated tumour growth at
micrometastatic sites mediated by angiogenesis after primary
tumour removal as well as tumor dormancy. Similar data are not
available for Asian populations. We sought to investigate
whether differences exist in the pattern of mortality hazard
function between Western breast cancer patients and their
Asian counterparts in Singapore, which may suggest underlying
differences in tumor biology between the two populations.
Methods We performed a retrospective cohort study of female
unilateral breast cancer patients diagnosed in Singapore
between October 1994 and June 1999. Data regarding patient
demographics, tumour characteristics and death were available.
Overall survival curves were calculated using the Kaplan-Meier
method. The hazard rate was calculated as the conditional
probability of dying in a time interval, given that the patient was
alive at the beginning of the interval. The life table method was
used to calculate the yearly hazard rates.
Results In the 2,105 women identified, 956 patients (45.4%)
had mastectomy alone. Demographic characteristics were as
follows: 86.5% were Chinese, 45.2% were postmenopausal,
38.9% were hormone receptor positive, 54.6% were node
negative and 44.1% had high histological grade. We observed
a double-peaked mortality hazard pattern, with a first peak in
mortality achieving its maximum between years 2 and 4 after
mastectomy, and a second large peak in mortality during year 9.
Analyses by subgroups revealed a similar pattern regardless of
T stage, or node or menopausal status. This pattern was also
noted in high-grade tumors but not in those that were well to
moderately differentiated. The double-peaked pattern observed
in Singaporean women was quantitatively and qualitatively
similar to those reported in Western series.
Conclusion Our study confirms the existence of a double-
peaked process in Asian patients, and it gives further support to
the tumour dormancy hypothesis after mastectomy.
Introduction
The time to event curve describes the cumulative event-free
time distribution at a given point after accrual in clinical trials.
Although it is widely reported throughout the oncology litera-
ture, it does not give direct information regarding changes in
event probability over time. Such information is highlighted
using the hazard function, which provides the failure rate at any
instant among survivors up to that point in time. It is also known
as the conditional failure rate or time-specific mortality rate.
Examination of the hazard function in graphical form can pro-
vide insight into the pattern of failure. For a treatment that
results in cure or prolongation of survival, a decreasing hazard,
at least for a period following successful treatment, would be
expected [1]. It is therefore somewhat counterintuitive that
independent researchers have discovered double-peaked
relapse and mortality hazard plots in breast cancer patients
treated with mastectomy alone [2-10]. Such double-peaked
patterns defy explanation by classical Gompertian tumour
kinetics within micrometastatic foci. Neither can they be
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adequately explained by the existence of distinct patient sub-
populations or by the frequency of follow up [2]. One hypo-
thesis suggests that the first recurrence peak corresponds to
surgery-induced phase transitions within micrometastatic foci
from nondividing single cell states to avascular growth states,
and from this state to a phase of vascularization and further
growth. The second peak is attributed to activation of
micrometastatic foci after several years of tumour dormancy
[11].
With increasing recognition that breast cancer is a heteroge-
neous disease comprising different subtypes with distinct bio-
logical behaviours [12], we sought to investigate whether a
double-peaked pattern of mortality hazard, similar to that found




The Singapore Breast Cancer Registry is a prospective cohort
of 3,809 females diagnosed with unilateral malignant breast
carcinoma from October 1994 to the end of June 1999 in Sin-
gapore. All patients registered were prospectively recruited,
and their medical records and pathologic reports were retro-
spectively evaluated.
Biodata including ethnicity (Chinese, Malay, Indian, or other),
date of birth, menopausal status and tumor characteristics
(oestrogen receptor [ER] and progesterone receptor [PR] sta-
tus, lymph node status, tumour histological grading, tumour
size and pathological T stage [13]) were recorded. Manage-
ment strategy (type of surgery, adjuvant therapy) was also
noted.
Women were considered to be postmenopausal following
spontaneous cessation of menses for 6 months or after bilat-
eral oophorectomy. Because the data used are derived from a
registry, no detailed information is available on general criteria
for adjuvant treatment administration and the methods used to
assess hormone receptor status.
Death status was obtained passively from the Department of
Cancer Informatics, National Cancer Centre Singapore for
patients who received treatment there. For the remaining
patients, death status was confirmed by electronic matching
with the national death registry. Registration within 2 days is
mandatory under Singapore law, and so the completeness of
this information can be confirmed as entirely reliable. All
women for whom death status was not captured were
assumed to be alive at 1 June 2005.
Statistical analysis
The analysis was focused on mortality. Survival time was cal-
culated from the date of surgery to the date of death or, for
those who were alive, it was censored at 1 June 2005. The
average interval between date of diagnosis and date of sur-
gery was 11 days. Survival curves were calculated using the
Kaplan-Meier product-limit estimator based on deaths from all
causes. Hazard ratios, summarizing differences between
groups, were estimated using Cox regression and the 95%
confidence intervals were obtained.
The annual mortality hazard rate, defined as the conditional
probability of dying in a time interval, given that the patient was
alive at the beginning of the interval, was calculated as follows
[14]: number of women who died within a particular postoper-
ative year/total number of women-years of follow up accumu-
lated in that particular year. Ten-year hazard plots with
corresponding 95% confidence intervals were examined for
patterns in the changing risk for mortality (Figure 2). To over-
come potential masking of underlying mortality hazard patterns
using fixed 1-year intervals (bin width), the kernel method of
smoothing (Figure 3) with half-width of 2 years was used.
Once selected, the deaths within the flexible bin closest in
time to the centre of the bin are given more weight in the aver-
aging process. Further successive bins along the time axis
overlap, so that a smoothed and continuous estimate of the
hazard is obtained [15].
All statistical analysis was completed using the Stata statisti-
cal software package (release 7.0; Stata Corporation, College




Of 3,809 female patients presenting with unilateral breast can-
cer, 339 (8.9%) were inoperable, 924 (24.3%) had wide exci-
sion, and 2546 (66.8%) underwent total mastectomy. Before
mastectomy all patients underwent staging investigations,
including liver function test, chest radiography, ultrasound
liver, skeletal survey and bone scan.
Among those who underwent mastectomy, 176 patients were
excluded because they either had neoadjuvant or palliative
treatment (chemotherapy or radiotherapy), and a further 265
patients were excluded because they either had pathological
Tis, T0, or T4 disease, or they had stage 4 disease or the stage
was unknown. In the remaining 2,105 women (half of whom
had received tamoxifen), 45.4% (67.2% of whom received
tamoxifen) underwent mastectomy alone, 29.0% received
adjuvant chemotherapy without radiotherapy, 6.8% received
radiotherapy without chemotherapy and 18.9% received both
modalities (Table 1). The mortality hazard patterns among
these four groups are examined in detail.
Patients who received adjuvant chemotherapy tended to be
younger, whereas the distribution of ethnic descent was simi-
lar across the four groups (Table 1). Patients with poor prog-
nostic features such as T2 or T3 disease, positive lymphAvailable online http://breast-cancer-research.com/content/9/2/R21
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nodes, higher tumour grade and ER-negative status were
more likely to have received adjuvant chemotherapy with or
without radiotherapy after mastectomy. Most of the patients
who had radiotherapy alone following mastectomy were post-
menopausal, and their tumours were larger than 1 cm with
moderate to poorly differentiated histological grade.
Overall survival
The median follow-up after mastectomy was 7.2 years. As
would be expected, the Kaplan-Meier survival curves (Figure
1) show that the poorest survival was in those receiving radio-
therapy alone or both radiotherapy and chemotherapy,
because these were selected for adjuvant treatment based on
poor prognostic features.
Table 1
Characteristics in patients treated with mastectomy by type of adjuvant therapy received







Combined chemotherapy and radiotherapy
(n = 396)
Age (years)
<35 14 (1.5) 43 (7.1) 4 (2.8) 24 (6.0) 85 (4.1)
35–49 245 (25.6) 390 (63.9) 32 (22.4) 251 (63.4) 918 (43.6)
50–64 404 (42.3) 161 (26.4) 64 (44.7) 106 (26.8) 735 (34.9)
>64 293 (30.6) 16 (2.6) 43 (30.1) 15 (3.8) 367 (17.4)
Ethnicity
Chinese 831 (86.9) 525 (86.1) 126 (88.1) 338 (85.4) 1820 (86.5)
Malay 65 (6.8) 62 (10.2) 9 (6.3) 40 (10.1) 176 (8.3)
Indian 46 (4.8) 19 (3.1) 7 (4.9) 14 (3.5) 86 (4.1)
Other 14 (1.5) 4 (0.6) 1 (0.7) 4 (1.0) 23 (1.1)
Menopausal status
Premenopausal 242 (25.3) 406 (66.6) 35 (24.5) 267 (67.4) 950 (45.1)
Uncertain 91 (9.5) 76 (12.5) 12 (8.4) 25 (6.3) 204 (9.7)
Postmenopausal 623 (65.2) 128 (20.9) 96 (67.1) 104 (26.3) 951 (45.2)
ER/PR status
+/+ 363 (47.1) 176 (32.6) 53 (45.7) 95 (27.9) 687 (38.9)
+/- 139 (18.0) 63 (11.7) 29 (25.0) 61 (17.9) 292 (16.5)
-/+ 41 (5.3) 37 (6.8) 2 (1.7) 21 (6.2) 101 (5.7)
-/- 228 (29.6) 264 (48.9) 32 (27.6) 163 (48.0) 687 (38.9)
Not done 185 70 27 56 338
Pathologic T stage
T1 488 (51.1) 209 (34.3) 38 (26.6) 70 (17.7) 805 (38.2)
T2 423 (44.3) 368 (60.3) 83 (58.0) 249 (62.9) 1123 (53.4)
T3 45 (4.7) 33 (5.4) 22 (15.4) 77 (19.4) 177 (8.4)
Lymph node (N) status
Positive 243 (25.4) 300 (49.2) 74 (51.8) 339 (85.6) 956 (45.4)
Negative 713 (74.6) 310 (50.8) 69 (48.2) 57 (14.4) 1149 (54.6)
Histological grading
Well 164 (21.2) 49 (8.8) 17 (13.3) 21 (5.7) 251 (13.8)
Moderate 369 (47.7) 218 (39.2) 57 (44.5) 125 (34.1) 769 (42.2)
Poor 240 (31.1) 289 (52.0) 54 (42.2) 221 (60.2) 804 (44.1)
Not done 183 54 15 29 281
Values are expressed as number (%). ER, oestrogen receptor; PR, progesterone receptor.Breast Cancer Research    Vol 9 No 2    Gao et al.
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Among the major ethnic groups in Singapore, Malay women
appear to have the poorest survival (Figure 1). When com-
pared with Chinese, the hazard ratio for these women is 1.59
(95% confidence interval 1.21–2.08), whereas for Indian
women it is 0.78 (95% confidence interval 0.48–1.29). After
adjustment for type of treatment received, these hazard ratios
remain essentially unchanged. There were insufficient patient
numbers to adjust further for differences in patient tumour
characteristics between ethnic groups.
Hazard rate
Chinese women: mastectomy alone
Because the Chinese comprise the largest ethnic group
(80%) in Singapore, and we were interested in comparing our
data with those reported by Demicheli and coworkers [5], we
first focused on these 831 women. Visual inspection of the
annual hazard rates presented in Figure 2a suggests that there
is a double-peaked pattern; one peak is rather flat and the sec-
ond is more pronounced. These are indicated by a gradual
increase in risk after surgery until 3 to 4 years, followed by a
gradual decline until year 8, and then a second rise to a maxi-
mum at 8 to 9 years, although the confidence intervals indicate
a lack of precision at each successive time point. However,
despite this rather subjective process, the peak times appear
to be close to the 3.5 and 8.5 years indicated by Demicheli
and coworkers (Figure 1) [5]. Also the mean annual hazard
rate of 0.04 is similar to their value of approximately 0.05.
The agreement between the peaks identified in our data and
those reported by Demicheli and coworkers [5] becomes even
more apparent in the corresponding kernel plot of Figure 3a.
From this, the estimated time of the first peak is at 2.5 years,
with hazard 0.04, and the second is at 9 years, with marginally
greater hazard of 0.05. However, with 30.6% (Table 1) of this
group comprising women aged 65 years or older, (noncancer)
mortality will play an increasing role. Beyond that time point,
the follow up data are sparse and so the (smoothed) hazard
estimates become unstable.
The double-peaked pattern is present in both node-negative
and node-positive patients, but the patterns are weak in the
former (Figure 4a) and more prominent in the latter (Figure 4b),
rising to a maximum hazard at 2 years of 0.1. The mean hazard
appears greater, and is relatively uniform over the 4-year to 8-
year period, in those whose tumours are T2 or T3 than in those
with T1 tumors, among whom there is evidence of a rise after
8 years (Figure 4c,d). There is a discernable but weak double-
peak among both premenopausal and postmenopausal
women (Figure 4e,f). A distinct peak is evident for poorly dif-
ferentiated tumours (Figure 4h) but not in well to moderately
differentiated tumors.
In these Chinese women treated with mastectomy alone (with-
out chemotherapy or radiotherapy), hormone receptor status
was known in 665 (80%) patients, nearly 70% of whom
received adjuvant tamoxifen. In those whose ER/PR status
was not known, 60% had received tamoxifen. A double-
peaked pattern is seen in both ER-positive and ER-negative
subgroups (Figure 4i,j). However, somewhat different mortality
curves were observed. The first peak for the ER-positive sub-
group occurs at 5 years, with a hazard of 0.041, and the sec-
ond occurs at year 8, with a hazard of 0.058 (Figure 4i). The
corresponding peaks for the ER-negative subgroup are at year
3 (hazard 0.072) and year 6 (hazard 0.055; Figure 4j).
Chinese women: mastectomy followed by adjuvant 
treatment
In those patients receiving chemotherapy alone (Figures 2b
and 3b) the mortality (mean hazard 0.025) is dissimilar to that
in women who underwent mastectomy alone. In contrast, in
patients receiving radiotherapy alone (Figures 2c and 3c) the
pattern of hazards (mean 0.047) is more variable. Both the
chemotherapy alone and radiotherapy alone groups exhibit an
early peak at about 2 years, but in the chemotherapy alone
group this is followed by gradual decline to a somewhat erratic
pattern, fluctuating around a hazard of 0.03. This is in contrast
Figure 1
Kaplan-Meier survival estimates Kaplan-Meier survival estimates. (a) Patients undergoing mastectomy 
alone and those receiving adjuvant chemotherapy or radiotherapy, or 
both. (b) By ethnic group. Chemo, chemotherapy; RT, radiotherapy.Available online http://breast-cancer-research.com/content/9/2/R21
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to patients receiving radiotherapy alone, in whom a second
and higher peak to a hazard of 0.076 occurs at 3.5 years.
However, this group includes only 148 patients (Table 1) and
ther are wide 95% confidence intervals for the hazard rates
(Figure 2c), and so no pattern is firmly established. In women
who received both chemotherapy and radiotherapy, in whom
the mortality rises until 1.5 years to an annual hazard of approx-
imately 0.081 and exhibits a plateau at this level until 6.5 years
before declining to a minimum at 8.5 years, the double-peak
pattern is not apparent (Figures 2d and 3d). As might be
expected, the mean hazard for this group, at 0.054, is quite
high. Clearly, the double-peak pattern is present in women
who underwent local therapy only (the mastectomy alone and
radiotherapy alone groups combined; Figures 2e and 3e), and
not in those who received systemic chemotherapy (Figures 3f
and 3f).
Malay and Indian women
Because the total numbers of women of Malay (n = 176) and
Indian (n = 86) ethnicity are small, the smoothed hazard plots
of the treatment groups are correspondingly less stable and
difficult to interpret (Figures 5 and 6). However, there are par-
allels both between these two ethnic groups and the patterns
in the Chinese (Figures 2 and 3), although these can only be
speculative.
Discussion
In the present study, conducted in a predominantly Asian pop-
ulation, we demonstrate the presence of a double-peaked
mortality hazard pattern among women treated with mastec-
tomy alone. This double-peaked pattern is observed in the var-
ious patient subgroups regardless of hormone receptor status,
menopausal status, node status, or T stage; this hints at a true
biological phenomenon, as opposed to distinct patient sub-
sets accounting for the separate peaks.
Confining our attention to patients of Chinese origin, we were
able to confirm the presence of a double peak but, compared
with the data reported by Demicheli and coworkers [5], these
peaks occurred at slightly different timings (2.5 and 9.0 years,
with corresponding peak hazards of 0.041 and 0.059; Figure
3a). We further verified that double peaks were more promi-
Figure 2
Hazard rates for death in ethnically Chinese breast cancer patients Hazard rates for death in ethnically Chinese breast cancer patients. (a) Mastectomy alone. (b) Adjuvant chemotherapy without radiotherapy. (c) 
Radiotherapy without chemotherapy. (d) Both modalities. (e) Local therapy only. (f) Systemic therapy. Note the different scale used for the hazard in 
panel d. Chemo, chemotherapy; RT, radiotherapy.Breast Cancer Research    Vol 9 No 2    Gao et al.
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nent in those women with positive nodes and more advanced
stage. In addition, although not reported in the Milanese data
[5], a double-peak was also found to be present in those with
ER-negative tumours.
Our findings are also consistent with those observed in other
published reports [5-10] and our study is, to the best of our
knowledge, the only one to date that confirms such findings in
a non-Caucasian population.
A second important finding was the absence of any double-
peaked mortality hazard pattern in women who received adju-
vant systemic therapy (with or without radiotherapy; Figures 2f
and 3f). In contrast, the double-peak pattern was evident in
women who received local therapy (Figures 2e and 3e). This
difference may be attributed to the fact that patients in these
two groups were biologically distinct, with a larger proportion
of women having nodal positivity and higher tumour grade in
the combined modality group compared with the mastectomy
alone group or radiotherapy alone group. The absence of a
double peak in the combined modality arm could also reflect
the impact of adjuvant therapy on the natural history of the dis-
ease. For example, Demicheli and coworkers [16] found a
single peak in the recurrence hazard (which is limited to the
first 4 years) in patients with node-positive breast cancer
receiving adjuvant treatment (cyclophosphamide, methotrex-
ate and 5-fluorouracil) as compared with a double peak in the
control arm (in which patients underwent no further treatment
after mastectomy). Saphner and coworkers [17] examined the
recurrence hazard of 3,585 women with early breast cancer
Figure 3
Smoothed hazard for death in ethnically Chinese breast cancer patients Smoothed hazard for death in ethnically Chinese breast cancer patients. (a) Mastectomy alone. (b) Adjuvant chemotherapy without radiotherapy. (c) 
Radiotherapy without chemotherapy. (d) Both modalities. (e) Local therapy only. (f) Systemic therapy. Note that the tail of the curve was removed 
because of the small number of available data. Chemo, chemotherapy; RT, radiotherapy.Available online http://breast-cancer-research.com/content/9/2/R21
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Figure 4
Smoothed hazard for death in ethnically Chinese breast cancer patients having mastectomy alone Smoothed hazard for death in ethnically Chinese breast cancer patients having mastectomy alone. (a) Lymph node negative. (b) Lymph node posi-
tive. (c) Pathological T1. (d) Pathological T2 or T3. (e) Premenopausal. (f) Postmenopausal patients. (g) Well to moderately differentiated. (h) 
Poorly differentiated. (i) ER positive. (j) ER negative. Note that the tail of the curve was removed because of the small number of available data. ER, 
oestrogen receptor.Breast Cancer Research    Vol 9 No 2    Gao et al.
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entered into seven Eastern Cooperative Oncology Group
adjuvant trials and demonstrated essentially single-peaked
hazard patterns.
It has been shown that mortality risk is associated with meno-
pausal status [5]. In the Milan series, node-positive premeno-
pausal patients exhibited an initial mortality wave covering
about 6 years, with a maximum at year 4, followed by a second
peak 8 years after surgery; postmenopausal patients, how-
ever, exhibited an early high mortality surge peaking at year 3,
followed by a modest increase at 8 years. In contrast, we
found only a weakly discernable double-peak among the pre-
menopausal and postmenopausal Chinese patients (Figure
4e,f). Part of this may be due to the greater heterogeneity of
the Singaporean patients, who were from a population cohort;
this contrasts with the Milan series of patients, who were
recruited in controlled clinical trials that would have applied
carefully defined eligibility criteria.
Patterns among the four broad treatment groups in those of
Malay and Indian origin suggest a peak hazard at about 2
years, but this should not be overstated because patient num-
bers are relatively small in these groups (Table 1, and Figures
5 and 6).
The study has some limitations because we did not have
access to recurrence data and were therefore unable to study
the association between relapse and mortality hazards. In
addition, 70% of women in the mastectomy alone group did
receive adjuvant tamoxifen, which is regarded as a form of sys-
temic therapy. However, excluding these patients from the
analysis, a double-peak mortality hazard pattern remains (data
not shown).
Figure 5
Smoothed hazard for death in ethnically Malay breast cancer patients Smoothed hazard for death in ethnically Malay breast cancer patients. (a) Mastectomy alone. (b) Adjuvant chemotherapy without radiotherapy. (c) 
Radiotherapy without chemotherapy. (d) Both modalities. (e) Local therapy only. (f) Systemic therapy. Note that the tail of the curve was removed 
because of the small number of available data. Chemo, chemotherapy; RT, radiotherapy.Available online http://breast-cancer-research.com/content/9/2/R21
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The kernel method of smoothing allows one to conduct a more
detailed examination of the changing hazard as compared with
the 'annual-bin' method utilized by, for example, Demicheli and
coworkers (Figure 1 in that report [5]) and our Figure 2. How-
ever, the kernel method of smoothing also involves a degree of
subjectivity, so that the relatively minor differences in peak
times noted may only reflect chance variations (or differences
in statistical methodology) and not systematic differences
between Singaporean and Italian women. The smoothed and
nonsmoothed estimates become less reliable as postsurgery
follow-up time increases and the number of observed deaths
declines. The follow up of the Singaporean women continues,
and patterns at 10 years after surgery and beyond will be
examined in due course.
Conclusion
In conclusion, we confirm the validity of findings of earlier
reports from Milan and elsewhere in some 2,105 South East
Asian women, mainly of Chinese ethnicity, who underwent
mastectomy for unilateral breast cancer. The risks close to the
identified double peaks suggest a hazard that is often double
that of the mean hazard for the particular treatment group over
time. We therefore provide further evidence for the view pre-
sented by Demicheli and coworkers [3] that a double-peak
pattern in the hazard function reflects an acceleration in
growth of metastases caused by primary tumour removal and
activation of dormant sites of micrometastases years after ini-
tial treatment. The presence of this phenomenon serves as a
reminder of the need for prolonged follow up and surveillance
in breast cancer survivors, and suggests that extended or
novel antiangiogenic adjuvant therapy may confer benefit in
selected patients. Only long-term follow-up research will be
able to establish whether newer generation therapies can
change the nature history of treated breast cancer and elimi-
nate the second peak.
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